Related references
Note: Only part of the references are listed.Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study
J. B. Cwikla et al.
ANNALS OF ONCOLOGY (2010)
Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate
Mattias Sandstrom et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide
David L. Bushnell et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention
Erik Vegt et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
High-Administered Activity In-111 Octreotide Therapy with Concomitant Radiosensitizing 5FU Chemotherapy for Treatment of Neuroendocrine Tumors: Preliminary Experience
Grace Kong et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2009)
Defining Pharmacokinetics for Individual Patient Dosimetry in Routine Radiopeptide and Radioimmunotherapy of Cancer: Australian Experience
J. Harvey Turner
CURRENT PHARMACEUTICAL DESIGN (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate
Flavio Forrer et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Anja Rinke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Highly Efficient In Vivo Agonist-Induced Internalization of sst(2) Receptors in Somatostatin Target Tissues
Bea Waser et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Neuroendocrine tumors of the diffuse neuroendocrine system
Bjorn I. Gustafsson et al.
CURRENT OPINION IN ONCOLOGY (2008)
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE:: the role of associated risk factors
Lisa Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours
Martijn van Essen et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate:: Toxicity, efficacy, and survival
Dik J. Kwekkeboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Molecular targeted therapy for carcinoid and islet-cell carcinoma
James C. Yao
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Therapeutic options for gastrointestinal carcinoids
Irvin M. Modlin et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?
R Glynne-Jones et al.
ANNALS OF ONCOLOGY (2006)
Validation of a personalized dosimetric evaluation tool (Oedipe) for targeted radiotherapy based on the Monte Carlo MCNPX code
S Chiavassa et al.
PHYSICS IN MEDICINE AND BIOLOGY (2006)
Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer:: a multicentric phase II study
A De Paoli et al.
ANNALS OF ONCOLOGY (2006)
Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities
WAP Breeman et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
A software tool for specifying voxel models for dosimetry estimation
E McKay
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2003)
Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings
M de Jong et al.
SEMINARS IN NUCLEAR MEDICINE (2002)
Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use
JC Reubi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2000)
Share Paper
